Please login to the form below

Not currently logged in
Email:
Password:

GSK appoints new chief financial officer

GSK has announced that Julian Heslop will retire as chief financial officer at the end of March 2011 and will be replaced by Simon Dingemans
GlaxoSmithKline (GSK) has announced that Julian Heslop will retire from his role as chief financial officer (CFO) and executive director at the end of March 2011. He will be replaced by Simon Dingemans who will take up the roles of chief financial officer designate and executive director with effect from January 2011.



Simon Dingemans, new CFO at GSK

Simon Dingemans




Dingemans will join GSK from investment bank Goldman Sachs. During his 25 year career in investment banking, Dingemans has worked across multiple sectors including pharmaceuticals and consumer healthcare. Recently, he worked with GSK on their joint project with Pfizer to establish specialist HIV company ViiV Healthcare.


GSK CEO, Andrew Witty, said: "In joining our executive team, Simon will bring valuable experience and capability to support us in our strategy to grow and diversify GSK's business through organic means and bolt-on acquisitions. He will also be responsible for delivering cost savings from our global restructuring programme and implementing further measures to simplify our operational model. I am delighted that someone of his calibre will be joining GSK."

9th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics